Two deals, one week
The US IPO calendar for the week of November 9 is thin, but the two deals most likely to price could hardly be more different. Rezera (RZRA), a Boston biotech, has set terms to raise about $200 million. vVardis (VVVV), a Swiss dental company backed by Apollo and OrbiMed, is seeking up to $228.6 million at a valuation near $4.4 billion.
Timing is not firm. Renaissance Capital expects Rezera to price this week, and sources disagree on exact dates for vVardis. Neither deal had priced at the time of writing, so everything below describes terms, not outcomes.
For founders and CFOs weighing a listing, the pair is a useful side-by-side. One company is asking the public market to fund a clinical program. The other is asking it to pay a premium for a growing, still loss-making commercial business.
Rezera: a raise that nearly equals the company
Rezera is selling 16.7 million shares at $11 to $13, or about $200 million, on Nasdaq, according to Renaissance Capital. Renaissance puts the fully diluted market value at the midpoint at about $254 million. By simple division, the offering equals roughly 79% of that value. That is a very large slice to sell at once, and it explains the pro forma numbers in the filing.
According to the company's amended S-1, Rezera held $3.9 million in cash at June 30, 2026. After the offering at the $12 midpoint, pro forma cash would be about $214.9 million. It lost $25.5 million in the first half of 2026 and $42.2 million in all of 2025, and its accumulated deficit stood at $210.7 million.
The use of proceeds is specific. Net proceeds of about $181.0 million at the midpoint, plus existing cash, are meant to carry its lead drug, ruvonoflast, an oral NLRP3 inhibitor, through topline data from a planned Phase 3 trial in peripheral artery disease. That trial is expected to start in the first half of 2027 and report in 2028. The filing also says the proceeds would not be enough to fund a Phase 2 trial of its second candidate, trabzanoflast, through topline data.
One detail matters for anyone reading demand signals. Glaxo Group Limited, an affiliate of GSK, has indicated interest in buying up to 2,083,333 shares, about $25 million at the midpoint. The prospectus states that such indications of interest are not binding. The company also signed a right of first negotiation and a clinical advisory board agreement with GSK this month, per the same filing. An anchor with a commercial relationship can help a small biotech's book, but it is not the same as a broad base of independent buyers.
vVardis: a growth story priced at a high multiple
vVardis is offering 9,523,810 Class A shares at $21 to $24, up to about $228.6 million, with a listing planned on the NYSE under VVVV, per Investing.com. Goldman Sachs and J.P. Morgan lead the deal. The fully diluted valuation at the top of the range is about $4.4 billion, against a private valuation the same report says was above $1 billion in April.
The business is real and growing. The company's preliminary figures show net revenue of $47.7 million to $49.2 million for the nine months ended September 30, 2026, more than double the $22.3 million a year earlier. It estimates a gross margin near 86%. Its product, Curodont, is a non-invasive cavity treatment sold through an exclusive partnership with Henry Schein (HSIC), and it reports use in more than 20,000 of roughly 110,000 targeted US practices.
The profit picture is less tidy. Projected nine-month net loss is $39.7 million to $41.3 million, roughly flat against $40.7 million a year earlier, although adjusted EBITDA loss narrowed to about $9.3 million from $17.1 million. Renaissance Capital reported $50 million of revenue for the 12 months ended June 30, 2026. Dividing the $4.4 billion top-of-range value by that figure gives roughly 88 times trailing revenue, my own calculation and a rough one, since the periods differ.
Governance is the other trade-off. The two co-founders will keep 87.0% of voting power through high-voting Class B shares, making vVardis a controlled company. Public buyers would be paying a growth multiple without much say in the outcome.
What this means for issuers
Three takeaways stand out for anyone planning a raise.
Cash runway shapes the deal. Rezera enters the process with $3.9 million in the bank. A company in that position has little leverage on price or timing, and the IPO is effectively its next financing round. vVardis has a private valuation history and large sponsors, which gives it room to test the range.
Anchors are signals, not commitments. Both the size and the non-binding nature of the GSK interest are worth modeling before assuming a book is covered.
Control is priced in. Dual-class structures are common in growth IPOs, but a founder holding 87% of votes narrows what buyers can ask for in governance terms.
What to watch next
First, whether each deal prices inside its range. A midpoint or better for Rezera would suggest buyers are willing to underwrite a Phase 3 program for a company with an accumulated deficit above $210 million. A cut below $11 would point the other way. Second, how vVardis trades relative to its range, given the valuation gap versus its last private round. Third, whether other issuers that have been waiting use any positive result as a reason to launch before the holiday period.
None of this is a recommendation on either stock. It is a look at the terms on offer, and the final price and size can differ from what was filed. Check the latest amended filings and a live IPO calendar before relying on any figure here.